Your patients may not have
to face chronic pain alone
There
i
thera s no AB-ra
peuti
ted
ce
OPAN
A® ER quivalent
to
with I
NTAC
®
OPANA® ER (oxymorphone HCl) Extended-Release tablets, CII with
INTAC® Technology are the only oxymorphone extended release tablets
that are designed to be crush resistant.*2
*The clinical significance of INTAC® technology or its impact on abuse/misuse
liability has not been established.
Generic oxymorphone HCl ER products are available but are not designed to be
crush-resistant and are not therapeutically equivalent to OPANA® ER with INTAC®
Widely available on managed care plans for 9 out of 10 covered patients.3
INDICATION
OPANA® ER is an opioid agonist indicated for the relief of moderate to severe
pain in patients requiring continuous around-the-clock opioid treatment for
an extended period of time.
Adverse reactions reported at (≥2%) in placebo-controlled trials were: na